Develops treatments for liver diseases and viral infections, leveraging proprietary technology to target specific pathogens.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company's lead drug candidate, ALG-010133, is an s-antigen transport-inhibiting oligonucleotide polymer currently in Phase Ib clinical trials for chronic hepatitis B (CHB). Additionally, ALG-000184, a capsid assembly modulator, is in Phase I clinical trials for the treatment of CHB. Aligos also pursues ALG-020572, an antisense oligonucleotide targeting HBsAg translation, and ALG-055009, a small molecule THR-ß agonist in Phase 1a/1b for non-alcoholic steatohepatitis (NASH).
Established in 2018 and headquartered in South San Francisco, California, Aligos has entered into strategic partnerships to advance its research and development initiatives. Collaborations with Luxna Biotech Co., Ltd., Emory University, Katholieke Universiteit Leuven, and Merck aim to accelerate the development and commercialization of innovative treatments. These partnerships focus on oligonucleotides targeting hepatitis B virus genome and coronavirus protease inhibitors, highlighting Aligos' commitment to leveraging cutting-edge technologies.
Aligos Therapeutics continues to expand its pipeline with promising candidates like ALG-125755, ALG-125097, and ALG-125819, which show potent inhibition of HBsAg release from HBV-infected cells. With a dedication to scientific excellence and patient-centered innovation, Aligos is poised to advance therapeutic options for patients affected by viral and liver diseases worldwide.